Background
Background: Transmitted HIV drug resistance (HIV-DR) may jeopardize the benefit of antiretroviral therapy (ART) and prevention (PrEP). Drug resistance testing is recommended at diagnosis of HIV in France and provides valuable insight for clinical decision-making and population-level monitoring.
Methods
Methods: We assessed the prevalence of HIV-DR and predicted susceptibility to HIV drugs among 3751 primary infected patients diagnosed between 2014 and 2025 within 6 months from the primary infection. Resistance to NRTIs, NNRTIs, PIs, INSTIs and capsid inhibitor was determined using the ANRS v35 algorithm. HIV-1 subtype was determined from the RT sequence using Blast tool and Los Alamos.
Results
Results: Among the 3751 participants, the majority were men (89%), of whom 70% were MSM and the median age was 34 years (range: 26-44). From 2014 to 2025, the prevalence of primary resistance was 15.8% to at least one drug from one class, 2.0% to two classes and 0.35% to three classes. None of the participants had resistant virus to four or five classes of drugs. The prevalence of HIV-DR was 2.9% for NRTIs, 9.6% for NNRTIs, 3.0% for PIs, and 4.8% for INSTIs. INSTI mutations were E157Q (2.6%), T97A (1.6%), E138K/T (0.2%), R263K (0.06%) and S230R (0.03%). None of the 56 patients with a capsid sequence available had HIV-DR. There was no trend over time in the proportion of viruses resistant to drug classes except for NNRTIs. In this case, resistance remained stable at 7% from 2014 to 2020, then increased to 17.6% in 2023. This increase is attributed to the high proportion of non-B subtypes, due to polymorphic mutations that confer resistance, and to the presence of transmission clusters with a E138A RT mutation. The prevalence of non-B subtypes increased from 39% in 2014 to 74% in 2025, with CRF02_AG being the most frequent (p<0.05). According to the 2024 French and EACS recommendations for ART initiation, the proportion of fully active triple ART between 2014 and 2024 varied from 99.2% to 87.2% in cases of NRTI- or INSTI-based regimens. For dual ART, sensitivity ranged from 99.2% to 97.4% for DTG/3TC, from 93.5% to 89.4% for DTG/RPV and CAB/RPV. When considering ARV used for PrEP, resistance to TDF/FTC, cabotegravir and lenacapavir was < 1.0%.
Conclusions
Conclusions: National population-level monitoring of HIV-DR associated with subtyping remains critical for informing future recommendations for antiretroviral treatment and prevention.